 |
|
Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study
Chang Hun Lee, Gwang Hyeon Choi, Hwa Young Choi, Sojung Han, Eun Sun Jang, Young Eun Chon, Young Chang, Kyung-Ah Kim, Do Young Kim, Hyung Joon Yim, Hye-Lin Kim, Sook-Hyang Jeong, In Hee Kim
Clin Mol Hepatol. 2023;29(3):779-793. Published online 2023 May 15 DOI: https://doi.org/10.3350/cmh.2023.0110
|
|
Citations to this article as recorded by
 Effect of direct-acting antivirals on disease burden of hepatitis C virus infection in South Korea in 2007–2021: a nationwide, multicentre, retrospective cohort study
Won Sohn, Soo Young Park, Tae Hee Lee, Young Eun Chon, In Hee Kim, Byung-Seok Lee, Ki Tae Yoon, Jae Young Jang, Yu Rim Lee, Su Jong Yu, Won-Mook Choi, Sang Gyune Kim, Dae Won Jun, Joonho Jeong, Ji Hoon Kim, Eun Sun Jang, Hwi Young Kim, Sung Bum Cho, Byoun
eClinicalMedicine.2024; 73: 102671. CrossRef Linvencovir: Paving the way for functional cure in hepatitis B
Jiwon Yang, Jonggi Choi
Clinical and Molecular Hepatology.2024; 30(2): 164. CrossRef Higher FIB-4 index at baseline predicts development of liver cancer in a community-based cohort with viral hepatitis
Makiko Kimura, Tomoki Nishikawa, Tetsuro Shimakami, Takeshi Terashima, Rika Horii, Masako Fukuda, Mika Yoshita, Noboru Takata, Tomoyuki Hayashi, Masaya Funaki, Kouki Nio, Hajime Takatori, Kuniaki Arai, Tatsuya Yamashita, Masao Honda, Junko Tanaka, Shuichi
Global Health & Medicine.2024;[Epub] CrossRef
|